Testing options | mySupport360

Testing options

The information gained from testing gives you and your family members the best chance at reducing your risk of future cancers. If you and your doctor decide that you are a candidate for genetic testing, there are many options available from Myriad Genetic Laboratories.

Myriad myRisk™ Hereditary Cancer

This test is a hereditary cancer panel that analyzes multiple genes, including BRCA1, BRCA2, MLH1, MSH2, MSH6, PMS2, EPCAM, MYH and others. Myriad myRisk combines genetic information with the personal and family history you give your healthcare provider to generate guideline-based management options to help you lower cancer risks.

BRACAnalysis®: a test for Hereditary Breast and Ovarian Cancer syndrome (HBOC)

  • Integrated BRACAnalysis
  • This test is used if no one else in your family has been tested, or no one else has had a positive result for a gene mutation. It checks for mutations in the BRCA1 and BRCA2 genes associated with HBOC syndrome.
  • Single Site BRACAnalysis
  • When a gene mutation has been previously identified in another family member, this screening test will look for that specific mutation only.
  • Multisite 3 BRACAnalysis
  • This BRACAnalysis test is used for the three most common mutations found in people of Ashkenazi, or Eastern European, Jewish ancestry.
  • BRACAnalysis Large Rearrangement Test (BART)
  • Most BRCA1 and BRCA2 gene mutations can be found with the standard BRACAnalysis test. However, there are some less common gene mutations that can only be found using a test called the BRACAnalysis Large Rearrangement Test (BART).

COLARIS®: a test for Hereditary Colon Cancer

    • COLARISPLUS
    • This test is used if no one else in your family has been tested or no one else has had a positive result for a gene mutation. It checks for gene mutations in the following genes: MLH1, MSH2, MSH6, PMS2,EPCAM, and MYH.
    • COLARIS AP®PLUS
    • This test aids assessment of the risk of developing hereditary colorectal polyps; it detects mutations in the APC and MYH genes, which cause adenomatous polyposis colon cancer syndromes.
    • Single Site COLARIS or Single Site COLARIS AP

This test is used if there is a known gene mutation in your family so your healthcare professional can look for a specific mutation.

  • Gene-Specific COLARIS
  • This test is appropriate for individuals with cancer who have had tumor analysis indicating they might have Lynch syndrome.

MELARIS®: a test for hereditary melanoma

This test detects inherited mutations in the p16 gene (also called CDKN2A or INK4A), which are associated with hereditary melanoma.

PANEXIA®: a test for hereditary pancreatic cancer

This test analyzes the PALB2 and BRCA2 genes, which are those most commonly mutated in families with hereditary pancreatic cancer.

Based on your family history and your personal needs, your doctor will decide which test is right for you. In addition to these risk-assessment tests, Myriad also offers other tests that can help cancer specialists optimize treatment plans for patients who have certain types of cancer.

Unique tests to aid cancer treatment planning

Additional testing is also available to help those who have already been diagnosed with cancer. A doctor might order one of these tests to learn more about tumor behavior or an individual patient’s possible response to therapy. The results of these tests help to make personalized treatment possible.

PROLARIS®: a test to assess prostate cancer aggressiveness

This test measures the expression levels of the genes involved in cell cycle progression. At the time of diagnosis, Prolaris can help to identify patients with less aggressive cancer who may be candidates for active surveillance. In addition, Prolaris can identify patients who appear clinically low-risk but have a more aggressive disease that requires more aggressive treatment. Visit Prolaris.com to learn more about this unique test.

PREZEON®: a test of PTEN gene function

In cancer patients, loss of PTEN function is associated with more aggressive disease. Studies have identified PTEN gene expression as being associated with improved response to cancer drugs in several cancers including breast, colon, and prostate.

  • A negative result assures the physician that he or she has ruled out many risks related to DPYD or TYMS variations.
  • A positive result allows physicians to adjust dosing, or to choose a different treatment that the patient may tolerate better.

""